Ardelyx, Inc. ARDX

What this company does

Ardelyx markets two therapies derived from tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that it discovered and developed. Tenapanor, marketed under the brand IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation. XPHOZAH is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy for patients who have an inadequate response to phosphate binders or are intolerant of any dose of phosphate binder therapy. At December 31, 2025, the company had 489 full-time employees, of whom 93 worked in research, development and manufacturing, 305 in sales and marketing and 91 in general and administrative activities. Its principal executive offices are located in Waltham, Massachusetts. The company operates in one business segment, the development and commercialization of biopharmaceutical products. The company was founded in October 2007 as a Delaware corporation under the name Nteryx and changed its name to Ardelyx, Inc. in June 2008.

Written from the business description in ARDELYX, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.